<p>Christoph Grevelding of Justus-Liebig-University in Germany will test the effectiveness of Imatinib, a cancer drug which inhibits kinase activity and cellular changes in cells, to impair and kill parasitic worms which carry Schistosomiasis. If successful, Imatinib could serve as a new drug therapy to fight this chronic disease which affects millions in developing countries.</p>


Christoph Grevelding of Justus-Liebig-University in Germany will test the effectiveness of Imatinib, a cancer drug which inhibits kinase activity and cellular changes in cells, to impair and kill parasitic worms which carry Schistosomiasis. If successful, Imatinib could serve as a new drug therapy to fight this chronic disease which affects millions in developing countries.